Bristol Myers Squibb (BMY) Stock May Be 46% Below Fair Value As FDA Approval Lands

Bristol-Myers Squibb stock has delivered a 40.6% 1 year return, while both its Discounted Cash Flow (DCF) intrinsic value estimate and market multiples currently point to the shares trading at a discount to what the business may be worth.

• The 40.6% gain over the past year suggests sentiment has improved, yet current valuation signals still indicate the market price may be below intrinsic value.
• Recent FDA accelerated approval for ZENBEXUS can support expectations for future cash flows, while the revived $6.7b lawsuit linked to delayed drug approvals may weigh on how investors price in legal and execution risk.
• Bristol-Myers Squibb screens as undervalued on most metrics, with 5 of 6 valuation checks pointing to a cheaper entry point than many peers.

For investors, the debate is whether that apparent discount, including an intrinsic value estimate suggesting the stock may be 45.6% undervalued, still offers enough upside after such a strong 12 month run.

Find out why Bristol-Myers Squibb's 40.6% return over the last year is lagging behind its peers.

Does Bristol-Myers Squibb Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model values Bristol-Myers Squibb by estimating the cash the business may generate for shareholders in the future and discounting it back to today.

Based on this 2 Stage Free Cash Flow to Equity model, Bristol-Myers Squibb is valued using last twelve month free cash flow of about $11.45b and projections that assume broadly stable to modestly declining free cash flows over time. On these inputs, the DCF estimate points to an intrinsic value of about $119 per share. Compared with the current share price, that implies the stock is 45.6% undervalued.

The revived $6.7b lawsuit over delayed drug approvals helps explain why the market may still be pricing Bristol-Myers Squibb below the intrinsic value suggested by its cash flows.

On this DCF view, Bristol-Myers Squibb stock appears undervalued relative to what its projected cash generation supports.

Our Discounted Cash Flow (DCF) analysis suggests Bristol-Myers Squibb is undervalued by 45.6%. Track this in your watchlist or portfolio, or discover 53 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Bristol-Myers Squibb.

Is Bristol-Myers Squibb a Bargain on Earnings?

P/E is a useful lens for Bristol-Myers Squibb because earnings remain a central focus for investors in large, established pharmaceutical companies. On this measure, the stock trades on a P/E of 14.2x, which is below both the Pharmaceuticals industry average of 16.4x and a wider peer average of 58.5x.

The tailored fair P/E for Bristol-Myers Squibb is 18.2x. This reflects what investors might typically pay given the company’s size, sector, profitability profile and risk factors. The current 14.2x level sits below that fair ratio, which suggests the market is applying a discount to the earnings stream even after the strong 1 year share price move and recent news flow around new therapies and legal proceedings.

On the P/E multiple, Bristol-Myers Squibb stock appears undervalued relative to what investors might usually pay for its earnings profile.

See what the numbers say about this price — find out in our valuation breakdown.

The Bristol-Myers Squibb Narrative: What Would Justify Today's Price?

Simply Wall St Narratives take the valuation puzzle around Bristol-Myers Squibb and present clear scenarios that explain which assumptions on growth, margins and earnings would need to hold for the stock to be worth materially more or less than today’s price. Each narrative links its figures to a specific view on how Bristol-Myers Squibb's growth, profitability and risks could evolve. You can revisit these narratives over time on the Community page as new information appears.

The community is split on Bristol-Myers Squibb, with one camp seeing meaningful upside still on offer and another viewing the stock as closer to fully priced.

Bull case: 19% undervalued

"Breakthrough partnerships such as the BioNTech deal position BMS's pipeline for industry leadership in immuno-oncology and radiopharmaceuticals, with accelerated speed to market and potential first-mover advantage in key tumor types creating a multi-billion dollar opportunity and robust long-term earnings growth…"

Read the full Bull Case to see why Bristol-Myers Squibb could be undervalued

Bear case: roughly fairly valued

"Bristol-Myers Squibb is facing significant upcoming patent cliffs, especially for blockbusters like Eliquis (generic in 2028) and Opdivo, raising the risk of generic and biosimilar competition, which could materially impact long-term revenue and earnings growth…"

Read the full Bear Case to see why Bristol-Myers Squibb could be overvalued

Do you think there's more to the story for Bristol-Myers Squibb? Head over to our Community to see what others are saying!

The Bottom Line

The intrinsic value estimate from the Discounted Cash Flow (DCF) model and the earnings multiple both point to Bristol-Myers Squibb screening as undervalued, even after recent news flow and legal headlines. The broad valuation checks look strong and the discount suggests the market is still cautious on future execution, legal outcomes and how the pipeline offsets key patent expiries. For you as an investor, the key question is whether that discount compensates for those risks or whether it reflects a value trap if cash flows and earnings do not evolve as optimists expect.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com